ArsenalBio Launches $85 Million Thanks to New Funding Round

Want to share this story?

ArsenalBio can now build its programmable cell therapy solution, thanks to its first funding round.

The company, which will create “highly effective and accessible immune cell therapies,” closed on a $85 million Series A funding round, backed by Kleiner Perkins, Westlake Village BioPartners, Parker Institute for Cancer Immunotherapy, University of California, San Francisco Foundation Investment Company, Euclidean Capital, and Osage University Partners.

ArsenalBio plans to  integrate technologies such as CRISPR-based genome engineering, scaled and high throughput target identification, synthetic biology, and machine learning to advance a new paradigm to discover and develop immune cell therapies, initially for cancer.